SEO URLwww.firestrike.ai/deals/avadel-pharmaceuticals-alkermes-acquisition-2026-5
acquisitionAnnounced · Feb 13, 2026PharmaceuticalsSource · MagazinesArticle · Factual
Alkermes acquires Avadel Pharmaceuticals
David Najork · Founding Software Engineer
Announced · Updated · 1 min read
Deal value
$2.1B
Target
Avadel Pharmaceuticals
NASDAQ: AVDL · Dublin, Leinster
Acquirer
Alkermes
Full Acquisition
Status
Pending
Alkermes agreed to acquire Avadel Pharmaceuticals. Reported deal value: $2.1B. Status: Pending. Sector: Pharmaceuticals. Target headquarters context: Dublin, Leinster, Ireland.
This page summarizes publicly available information about the transaction as of 2026-02-13. Figures and status may change as filings and press coverage update.
Alkermes completed its acquisition of Avadel Pharmaceuticals plc , adding LUMRYZ , a once-at-bedtime treatment for cataplexy or excessive daytime sleepiness in narcolepsy, to Alkermes ’ commercial portfolio
Deal timeline
Announced
Feb 13, 2026 · sleepreviewmag.com
Additional milestones (proxy, vote, close) appear as filings and press updates are indexed.
Sector context
This transaction is classified in Pharmaceuticals with a reported deal value of $2.1B. Figures and status may change as sources update.
Sources: sleepreviewmag.com · Primary article · FireStrike proprietary index